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Abstract
Background: Alzheimer's disease (AD) is characterized by early and region-specific declines in
cerebral glucose metabolism. Ketone bodies are produced by the body during glucose deprivation
and are metabolized by the brain. An oral ketogenic compound, AC-1202, was tested in subjects
with probable AD to examine if ketosis could improve cognitive performance.
Methods: Daily administration of AC-1202 was evaluated in 152 subjects diagnosed with mild to
moderate AD in a US-based, 90-day, randomized, double-blind, placebo-controlled, parallel-group
study. Subjects were on a normal diet and continued taking approved AD medications. Primary
cognitive end points were mean change from Baseline in the AD Assessment Scale-Cognitive
subscale (ADAS-Cog), and global scores in the AD Cooperative Study – Clinical Global Impression
of Change (ADCS-CGIC). AC-1202 was compared to Placebo in several population groups,
including: intention-to-treat (ITT), per protocol, and dosage compliant groups. Results were also
stratified by APOE4 carriage status (a predefined analysis based on the epsilon 4 (E4) variant of the
apolipoprotein E gene). This trial was registered with ClinicalTrials.gov, registry number
NCT00142805, information available at http://clinicaltrials.gov/ct2/show/NCT00142805
Results: AC-1202 significantly elevated a serum ketone body (β-hydroxybutyrate) 2 hours after
administration when compared to Placebo. In each of the population groups, a significant difference
was found between AC-1202 and Placebo in mean change from Baseline in ADAS-Cog score on
Day 45: 1.9 point difference, p = 0.0235 in ITT; 2.53 point difference, p = 0.0324 in per protocol;
2.6 point difference, p = 0.0215 in dosage compliant. Among participants who did not carry the
APOE4 allele (E4(-)), a significant difference was found between AC-1202 and Placebo in mean
change from Baseline in ADAS-Cog score on Day 45 and Day 90. In the ITT population, E4(-)
participants (N = 55) administered AC-1202 had a significant 4.77 point difference in mean change
from Baseline in ADAS-Cog scores at Day 45 (p = 0.0005) and a 3.36 point difference at Day 90 (p
= 0.0148) compared to Placebo. In the per protocol population, E4(-) participants receiving AC-
1202 (N = 37) differed from placebo by 5.73 points at Day 45 (p = 0.0027) and by 4.39 points at
Day 90 (p = 0.0143). In the dosage compliant population, E4(-) participants receiving AC-1202
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differed from placebo by 6.26 points at Day 45 (p = 0.0011, N = 38) and 5.33 points at Day 90 (p
= 0.0063, N = 35). Furthermore, a significant pharmacologic response was observed between
serum β-hydroxybutyrate levels and change in ADAS-Cog scores in E4(-) subjects at Day 90 (p =
0.008). Adverse events occurred more frequently in AC-1202 subjects, were primarily restricted
to the gastrointestinal system, and were mainly mild to moderate in severity and transient in nature.
Conclusion: AC-1202 rapidly elevated serum ketone bodies in AD patients and resulted in
significant differences in ADAS-Cog scores compared to the Placebo. Effects were most notable in
APOE4(-) subjects who were dosage compliant.
Background
Alzheimer's disease (AD) is a common, age-associated,
progressive, neurodegenerative disease. Risk of develop-
ing the most common form of AD (sporadic or late onset)
is principally linked to age, and the carriage status of the
epsilon 4 (E4) variant of the apolipoprotein E gene
(APOE). APOE4 behaves in a dominant, dose-dependent
manner; a single copy increases risk of developing AD
approximately 3 fold, while two copies increases risk
approximately 10 fold (for review of APOE see [1]). Clin-
ically, AD is characterized by progressive decline in mem-
ory and language, and pathologically by accumulation of
senile plaques and neurofibrillar tangles. Another promi-
nent feature of AD is regional cerebral hypometabolism.
Early imaging studies revealed low cerebral metabolic
rates of glucose use (CMRglu) in subjects with probable
AD [2], and this is now recognized as a general feature of
the disease [3]. The most commonly affected areas include
the posterior cingulate, parietal, temporal and prefrontal
regions [4]. These deficits can be detected in pre-sympto-
matic, at risk individuals, such as E4 carriers, as young
adults. Such changes have been detected in cognitively
normal subjects well before there is widespread neuronal
loss or predicted plaque deposition, suggesting that low
CMRglu is an early event in the disease [5].
The cause of the hypometabolism remains unclear and
may be due to loss of neurons or dendritic fields. Alterna-
tively, hypometabolism has been attributed to the action
of AD-specific factors. Amyloid beta (Aβ) [6] and frag-
mentation of the ApoE4 protein [7] have both been impli-
cated in dys-regulation of mitochondrial function. In
addition, several authors have proposed changes in insu-
lin signaling as a potential contributor to the develop-
ment of hypometabolism [8-12]. Regardless of its cause,
therapies aimed at correcting cellular metabolism may
prove beneficial to the AD patient [13].
One such promising therapy is the induction of ketosis
(for overview see [14]). Under normal circumstances, the
main energy substrate for the brain is glucose. However,
under certain situations, such as extended fasting, the liver
will produce ketone bodies for use by extrahepatic tissues,
including the brain. Three compounds are normally con-
sidered ketone bodies: β-hydroxybutyrate (BHB), acetoac-
etate (ACA) and acetone. Ketone bodies are an efficient
fuel for cells [15,16].
Levels of circulating ketone bodies can be raised by adher-
ence to a low-carbohydrate, high-fat, ketogenic diet.
Ketogenic diets have been used extensively for the reduc-
tion of seizure frequency in children with refractive epi-
lepsy [17] and have gained interest in several other
neurological conditions, including amyotrophic lateral
sclerosis [18], traumatic brain injury [19] and ischemia
[20] (for review see [14,21,22]). In addition, several pre-
clinical studies have suggested that induced ketosis may
be beneficial in AD. For example, the toxic effects of the
Aβ peptide in cultured neurons were shown to be miti-
gated by incubating the cells with BHB [23]. Also, a
ketogenic diet reduced total Aβ40 and Aβ42 in a trans-
genic mouse model of AD after 38 days of feeding [24].
Alzheimer's disease patients frequently undergo changes
in food preference toward sweet, carbohydrate-rich foods
[25-27], which would make compliance to a ketogenic
diet difficult. Therefore, AC-1202, a form of medium
chain triglycerides (MCTs), was developed to safely ele-
vate serum ketone bodies even in the presence of carbohy-
drate in the diet. MCTs were chosen for this study due to
their safety profile [28], and long historical use in lipid
malabsorption disorders and ketogenic diets [29]. Due to
the unique physical properties of AC-1202, it is metabo-
lized differently from the more common long chain trig-
lycerides (LCT) [30]. If sufficient amounts of AC-1202 are
consumed, a mild state of ketosis can be induced without
modification of the diet. In a pilot study of mild to mod-
erate AD patients, induction of ketosis by AC-1202 rap-
idly improved cognitive performance in subjects lacking
the APOE4 allele [31].
The primary aim of the present study was to assess
whether daily dosing of AC-1202 in mild to moderate AD
subjects would improve cognitive performance as meas-
ured by change from Baseline in the AD Assessment Scale-
Cognitive subscale (ADAS-Cog), and global score in the
AD Cooperative Study – Clinical Global Impression of
Change (ADCS-CGIC) after 90 days. Additional outcomesNutrition & Metabolism 2009, 6:31 http://www.nutritionandmetabolism.com/content/6/1/31
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investigated included how cognitive scores were influ-
enced by APOE4 genotype status, as our earlier acute dos-
ing study suggested that AD patients who lacked an
APOE4 allele may respond better to ketosis [31].
Methods
Participants
Subjects were screened for eligibility at one of 23 clinical
sites based within the U.S. Eligible subjects were outpa-
tients with a diagnosis of dementia of the Alzheimer type
of mild to moderate severity according to NINCDS-
ADRDA and DSMIV criteria, with a MMSE score of
between 14 and 24 (inclusive) at Screen. Diagnosis of
probable AD was performed by qualified physicians. A CT
or MRI within 24 months prior to Screen had to show no
signs of tumor, structural abnormality, or degenerative
disease. Subjects were required to have a Modified
Hachinski Ischemia Scale score ≤ 4.
Key exclusion criteria at Screen were: major depression as
determined by a Cornell Scale for Depression in Demen-
tia score of ≥ 13, clinically-significant hypothyroidism as
determined by thyroid function assessment, clinically-sig-
nificant B12 deficiency within 12 months prior to Base-
line, clinically-significant renal disease or insufficiency,
clinically-significant hepatic disease or insufficiency, and
any type of diabetes.
Subjects receiving currently approved AD medications
were eligible for enrollment in the study provided that
they had been maintained on stable dosing for at least 3
months prior to enrollment, and were required to remain
on stable dosing throughout the duration of the study.
Ethics
The trial was carried out with institutional review board
approval (Essex Institutional Review Board, Lebanon, NJ)
and in accordance with the principles of the Declaration
of Helsinki. Subjects and their caregivers provided written
informed consent, which included an optional written
provision for genotyping. At their discretion, participants
could consent to be tested for APOE, and/or additional
DNA markers. Genetic information was not shared with
site personnel or study participants. All clinical site mon-
itoring and data management procedures were carried out
in accordance with FDA and ICH Good Clinical Practice
Guidelines.
Interventions
Investigational product
AC-1202 is a medium chain triglyceride composed of
glycerin and caprylic acid (C8:0). The chemical name is
1,2,3-propanetriol trioctanoate (also known as tricaprylin
or trioctanoin). The CAS registry number is 538-23-8 and
molecular formula C27H50O6 (MW 470.69). The MCT for
this study was NeoBee 895® (Stepan Chemical Company).
NeoBee 895 is a common food ingredient, made using
glycerin from vegetable oil and fatty acids from coconut or
palm kernel oil. NeoBee 895 is an MCT wherein >95% of
the fatty acids are C8:0 with the remainder consisting of
C6:0 and C10:0 fatty acids.
Investigational product was formulated as an emulsified
spray dried powder consisting of 33% AC-1202, 64% gum
Acacia (Instagum, CNI) and 2.6% syloid (244 FP, Grace
Davison). Placebo was isocaloric to the active formula-
tion, and consisted of a mixture of 51% gum acacia, 37%
dextrose, 10% safflower oil and 2% syloid (prepared by
The Chemins Company). Investigational product was
given as a powder packaged in 30 gram sachets containing
either active (equivalent to 10 grams of AC-1202) or
matching Placebo.
The contents of the sachets were mixed in one 8 oz. glass
of a liquid such as water, milk, or juice prior to consump-
tion. These instructions were later amended to recom-
mend reconstitution with a meal replacement drink
(Ensure™, Abbott Laboratories, Inc) to improve product
tolerability. For the first seven days of the study, subjects
received one 30 gram sachet daily. On Day 8, the dose was
increased to two 30 gram sachets daily (equivalent to 20
grams AC-1202), which was continued through Day 90.
Daily doses were administered during breakfast, except on
clinic visit days when the participants were administered
investigational product at the clinic and asked to eat
breakfast prior to their scheduled visit. On Day 104, a
washout visit was conducted two weeks following the last
product administration.
Apolipoprotein E Genotype
High molecular weight DNA was isolated from whole
blood for determination of APOE genotype using stand-
ard techniques. Genotyping was performed using allele
specific extension by TechnoSynapse Inc. (Douglas Hos-
pital Research Center, Verdun, Quebec, Canada) as previ-
ously described [32].
Study Visits
Participants were scheduled for five study visits: Screen-
ing, Baseline, and post-baseline Days 45, 90, and 104 (± 3
days). At Screening, subjects and caregiver provided writ-
ten informed consent and were assessed for eligibility to
enter the study. Screening assessments included: demo-
graphics, medical/surgical history, NINCDS-ADRDA crite-
ria, DSM-IV criteria for dementia, Modified Hachinski
Ischemia Scale, prior and concomitant medications, phys-
ical examination, height, weight, vital signs, CT scan/MRI
(if not previously performed within the last 24 months),
ECG, TSH, B12, BHB serum level, safety laboratory assess-
ments, ADAS-Cog, MMSE and Cornell Scale for Depres-Nutrition & Metabolism 2009, 6:31 http://www.nutritionandmetabolism.com/content/6/1/31
Page 4 of 25
(page number not for citation purposes)
sion in Dementia. Participants who qualified for the study
returned for a Baseline visit (within 4 weeks of the Screen-
ing visit). Baseline assessments included: adverse events
(since initiation of Screen), concomitant medications,
vital signs, ADAS-Cog, ADCS-CGIC and MMSE. A blood
sample was taken for serum BHB levels prior to dosing
and 2 hr post-dosing. Visit 3 occurred 45 days (± 3 days)
after the Baseline visit, and is referred to as Day 45. Day 45
assessments included: adverse events, concomitant medi-
cations, vital signs, ADAS-Cog, ADCS-CGIC and MMSE. A
blood sample was taken for serum BHB levels prior to
dosing and 2 hr post-dosing. Visit 4 occurred 90 days (± 3
days) after the Baseline visit and is referred to as Day 90.
Day 90 assessments included: adverse events, concomi-
tant medications, vital signs, ADAS-Cog, ADCS-CGIC and
MMSE. A blood sample was taken for serum BHB levels
prior to dosing and 2 hr post-dosing. Day 90 was the last
day investigational product was administered. Visit 5
occurred 104 days (± 3 days) after the Baseline visit, and
is referred to as Day 104. Day 104 assessments included:
adverse events, concomitant medications, vital signs,
weight, physical examination, ECG, safety labs, ADAS-
Cog, ADCS-CGIC, and MMSE. A final blood sample was
taken for serum BHB levels. Day 104 assessments exam-
ined performance after a two week washout period.
Objectives
The primary aim of the present study was to assess if daily
dosing of AC-1202 in mild to moderate AD patients
would improve scoring on ADAS-Cog and ADCS-CGIC
over a period of 90 days. A secondary outcome examined
whether or not daily dosing of AC-1202 would improve
scoring on MMSE. Ancillary objectives, as defined in the
protocol, examined changes in ketone body levels post-
dose, and whether efficacy was influenced by the carriage
status of the epsilon 4 variant of the APOE gene.
Outcomes
Cognitive testing
As required by the protocol, all cognitive testing was car-
ried out by trained physicians, psychologists, nurses,
social workers, and/or research coordinators under the
direct supervision of the Principal Investigator.
The ADAS-Cog generally requires 30 to 45 minutes to
complete, is one of the most widely used cognitive tests
for anti-dementia drugs in the United States, and is fre-
quently considered the "gold standard" in evaluating cog-
nitive outcomes. The ADAS-Cog subscale consists of 11
tasks measuring cognitive abilities in memory, language,
orientation, and praxis. The test includes seven perform-
ance items and four clinician-rated items, with a total
score ranging from 0 (no impairment) to 70 (severe
impairment). The memory items includes two perform-
ance items (word recall and word recognition), and one
clinician rated item (remembering test instructions). In
word recall, the subject is shown ten words on flash cards
and then asked to recall the words in any order. In word
recognition, the subject is read aloud 12 words from flash
cards. The cards containing the 12 words read to the
patient are then mixed with 12 new word containing
cards, and all 24 cards shown to the subject. The subject is
then asked to distinguish the new words from the words
that were read aloud. Language items include two per-
formance items (naming objects and following com-
mands) and three clinician rated items (spoken language
ability, word finding difficulty, and comprehension of
spoken language). In naming objects, the subject is pre-
sented with real objects (such as pencil, wallet, or comb)
and asked to name them. In the clinician rated language
items, the clinician evaluates the subjects' overall ability
to understand and communicate spoken language during
the course of the test. The orientation item consists of one
performance test, in which the subject is asked a series of
questions related to where the subject physically is located
and time and date. Praxis items include two performance
items (constructional and ideational). In constructional
praxis, the subject is asked to draw several specific geomet-
ric shapes. In ideational praxis, the subject is asked to per-
form a task, such as mailing a letter, and is scored on the
ability to complete the task. The higher the ADAS-Cog
score, the more impaired the subject. Lowering of the
ADAS-Cog score is a measure of cognitive improvement.
The MMSE is a simple test used primarily for screening for
dementia. It can be administered in 5–10 minutes. The
MMSE test measures several cognitive areas including: ori-
entation, word registration, calculation, word recall, lan-
guage and visual construction. Orientation (10 points) is
measured by a series of questions relating to time and
place (What is the year? What is the month? What state are
we in?). Word registration (3 points) is measured by read-
ing the subject three words and then the subject is asked
to repeat them. Attention and calculation (5 points) is
measured by asking the subject to count backward from
100 by 7 s. Word recall (3 points) is measured by asking
the subject to recall the 3 words from the word registration
test. Language (8 points) is measured by asking the subject
questions requiring the patient to name objects such as
pencil or a wallet. Visual construction (1 point) is meas-
ured by having the subject draw a specific geometric
shape. Higher scores on MMSE indicate less impairment.
The MMSE is much less sensitive than the ADAS-Cog to
change, yet is advantageous in that it can be easily admin-
istered.
The ADCS-CGIC is used to assess a meaningful clinical
change over time. The ADCS-CGIC focuses on clinicians'
observations of change in the subject's cognitive, func-
tional and behavioral performance from Baseline status.Nutrition & Metabolism 2009, 6:31 http://www.nutritionandmetabolism.com/content/6/1/31
Page 5 of 25
(page number not for citation purposes)
Unlike ADAS-Cog or MMSE, CGIC takes into account a
subject's overall function in the cognitive, behavioral and
functional activity domains. The CGIC consists of two
parts. Part I is the Baseline evaluation during which the
clinician interviews the patient and the caregiver to estab-
lish a reference point for future ratings. Part II is the fol-
low-up interview with the patient and caregiver, and is
used to evaluate the overall status of the patient relative to
the reference Baseline interview. The CGIC uses a seven
point scale, from 1 (marked improvement) to 7 (marked
worsening). Therefore, like the ADAS-Cog, lower scores
indicate improved performance. (Note: due to a printing
error in the original Case Report Forms (CRFs), a six-point
scale was initially used that inadvertently omitted the cat-
egory "minimal improvement." The scale was revised to
include the full seven-point scale at a later time point.)
Serum β-hydroxybutyrate
Pre- and post-dosing serum samples were collected and
analyzed by Allied Research International (formerly
SFBC) of Miami, FL using the BHB Liquicolor® diagnostic
kit supplied by Stanbio Laboratories (Boenre, TX). The
normal range (12-hour fasting) is 0.02 mM to 0.27 mM.
Safety analyses
Safety evaluations included physical examinations, vital
sign measurements, routine serum chemistry and hema-
tology tests, urinalyses and electrocardiograms performed
at Screen and Day 104. Adverse events and any changes in
concomitant medication administration were recorded at
all clinic visits.
Sample size
The targeted sample size of 100 (50 AC-1202 and 50 Pla-
cebo) was determined empirically. Due to the exploratory
nature of this study and the lack of clinical/statistical ref-
erences for ADAS-Cog change effect sizes associated with
ketosis, the formal statistical power could not be calcu-
lated.
Randomization
Subjects were randomized in a 1:1 ratio to receive either
AC-1202 or matching Placebo for 90 days. A permutated
block randomization code with a block size of 4 was used.
Subjects were issued study kits labeled with a unique site
and subject number. Near the end of the study, new par-
ticipants entering the study were assigned to either AC-
1202 or Placebo by an un-blinded independent medical
monitor in such a manner as to obtain approximately 50
subjects who completed the study within each group. All
clinical site personnel remained blinded throughout the
entire course of the study. This intentional allocation
resulted in an imbalance in the final number of rand-
omized participants in each of the study groups; 86 rand-
omized to AC-1202 and 66 randomized to Placebo
(Figure 1). There was no crossover of participants. All sub-
jects remained in their assigned group throughout the
course of the study.
Blinding
The participants, those administering the interventions,
and those assessing the outcomes were blinded to group
assignment. The double-blinding was achieved through
Study randomization and group allocation for the ITT popu- lation Figure 1
Study randomization and group allocation for the 
ITT population.
253 Assessed for eligibility
152 Enrolled and assigned
101 Excluded
89 Did not meet inclusion criteria
12 Refused to participate
86 Allocated to AC-1202 66 Allocated to placebo
3 Lost to follow-up
35 Discontinued
20 Adverse events
8 Withdrew consent
2 Perceived lack of efficacy
1 Protocol violation
1 Relocation
3 Other
Of these 38, 9 lacked a post-
Baseline  visit and were not 
analyzed for efficacy
2 Lost to follow-up
12 Discontinued
4 Adverse events
5 Withdrew consent
2 Perceived lack of efficacy
1 Protocol violation
0 Other
Of these 14, 3 lacked a post-
Baseline visit and are were not 
analyzed for efficacy
77 Analyzed 63 Analyzed
67 APOE Genotyped 57 APOE Genotyped
ITT Population
ITT/Genotyped 
PopulationNutrition & Metabolism 2009, 6:31 http://www.nutritionandmetabolism.com/content/6/1/31
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the production and use of a Placebo similar in taste and
appearance to the investigational product AC-1202.
Statistical Methods
As defined by the protocol, an intention-to-treat (ITT)
analysis was used as the primary analysis of efficacy. The
ITT population was defined as all subjects who were ran-
domized, administered at least one dose of investigational
product, and completed at least one follow-up visit. For
those subjects in the ITT population, missing efficacy data
(i.e. ADAS-Cog, MMSE and ADCS-CGIC) was imputed
using the last observation carried forward (LOCF)
method. The primary end points established a priori were
change from Baseline at Day 90 in ADAS-Cog and com-
parison of the global scores of ADCS-CGIC at Day 90. The
secondary outcome was change from Baseline at Day 90
in the MMSE score. Pre-defined additional analyses
included interactions between cognitive outcomes and
APOE genotype, safety, tolerability and BHB concentra-
tion levels. Furthermore, due to the limitations of ITT w/
LOCF, additional analyses were conducted on per proto-
col and dosage compliant populations.
An overall two-way ANCOVA was used to evaluate the
cognitive scores, along with genotype effects and cognitive
scores by genotype interactions for 2 hour post-dose
serum BHB levels at Day 90. The ANCOVA model
included independent factors for group assignment, gen-
otype, and group assignment by genotype interactions. A
variable for Baseline serum BHB level was included as a
covariate. Correlations between the 2 hour serum BHB
level on Day 90 and the change from Baseline ADAS-Cog
total score was determined by Pearson correlation statis-
tics.
Summary statistical analyses were provided by SIRO Inc.
Mumbai, India; ANOVA and ANCOVA analyses were per-
formed by JJo Inc. Breckenridge, CO, USA; and Accera Inc.
Broomfield, CO USA.
Accera funded the study, designed the protocol, and either
conducted or commissioned the data analysis and inter-
pretation. The data are maintained on file at the offices of
Accera, Inc Broomfield, CO.
Results
Participant flow/Numbers analyzed
Figure 1 illustrates the trial participant profile. Two hun-
dred fifty-three participants with a diagnosis of probable
AD were screened between October, 2004 and March,
2006. Of the 253 participants screened, 152 were enrolled
in this study. The ITT population was defined in the pro-
tocol as all subjects who were administered at least one
dose and completed at least one follow-up visit subse-
quent to Baseline. One hundred and forty subjects met
these criteria and comprise the ITT population, of whom
77 were in the AC-1202 group and 63 in the Placebo
group (Figure 1). Fifty-two subjects withdrew before Day
104; twenty-four were due to adverse events (AEs), with
the majority in the AC-1202 group (Figure 1). One-hun-
dred thirty-five subjects (n = 75 AC-1202 (AC); n = 60 Pla-
cebo (PL)) consented to genotyping for the APOE locus.
Of these 135 subjects, 124 (n = 67 AC; n = 57 PL) were in
the ITT population. These 124 subjects were used in the
analysis of APOE4 effects.
Recruitment
This was a randomized, double-blind, placebo-control-
led, parallel-group, multi-center trial sponsored by Accera,
Inc. of Broomfield, CO. It was conducted between Octo-
ber 5, 2004 and June 29, 2006 at 23 centers located within
the United States. A list of investigator sites is found in
Table 1. This was an out-patient study, and recruitment
and testing was performed in individual investigators'
clinical sites. All investigators in this trial were pre-quali-
fied for study participation based on their academic train-
ing and specialty area of practice. Recruitment was done
by individual investigator sites and consisted primarily of
advertisements in local newspapers and on local radio sta-
tions.
Baseline Data
Baseline characteristics for Placebo and AC-1202 groups
are shown in Table 2. Placebo and AC-1202 groups were
well matched for age, height, weight and sex. Placebo and
AC-1202 groups were also comparable in terms of Base-
line MMSE and ADAS-Cog scores. Sixty-six of 86 (78.7%)
AC-1202 subjects and 55 of 66 Placebo subjects (83.3%)
were taking currently approved AD medications. The pro-
portion of subjects taking more than one AD medication
was higher among Placebo subjects than among AC-1202
subjects (24 of 86 [27.9%] AC; 24 of 66 [36.4%] PL). Of
the genotyped subjects, fifty-six percent of the subjects
were E4(+) (n = 69, 55.6%), and forty-four percent were
E4(-) (n = 55, 44.4%). E4(+) and E4(-) participants were
not significantly different in age, sex, Baseline ADAS-Cog,
or Baseline MMSE (Table 3). The proportion of subjects
taking individual concomitant AD medications was simi-
lar among E4(-) and E4(+) subjects, however, more E4(+)
subjects (70%) were taking memantine than E4(-) sub-
jects (50%).
Extent of Exposure
One hundred fifty-two subjects were randomized in this
study (86 AC; 66 PL) and received at least one dose of
investigation product. Subjects were permitted to inter-
rupt or reduce their doses of investigational product, with
the permission of principal investigators, if necessitated
by adverse events. Subjects in the Placebo group received
higher cumulative doses and remained on-study for aNutrition & Metabolism 2009, 6:31 http://www.nutritionandmetabolism.com/content/6/1/31
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Table 1: Investigators and sites
Site # Investigator Name Institution Name, location
100 Mildred V. Farmer, MD Meridien Research
Tampa, FL 33606
St. Petersburg, FL 33709
Brooksville, FL 34613
101 Margarita Nunez, MD Comprehensive NeuroScience
St. Petersburg, FL 33702
102 David Sack, MD Comprehensive NeuroScience
Cerritos, CA 90703
103 Murray A. Kimmel, DO KimmelCare, Family Practice, P.A.
Melbourne, FL 32935
104 Kerri L. Wilks, MD Baumel-Eisner Neuromedical Institute
Ft. Lauderdale, FL 33321
Miami Beach, FL 33154
Boca Raton, FL 33486
105 Stephen Flitman, MD 21st Century Neurology
Phoenix, AZ 85013
106 Richard Hubbard, MD The Southwest Institute for Clinical Research
Rancho Mirage, CA 92270
107 Daniel E. Grosz, MD Pharmacology Research Institute
Northridge, CA 91324
Los Alamitos, CA 90720
Riverside, CA 92506
Newport Beach, CA 92660
108 Malcolm Stewart, MD Dallas, TX 75231
109 Thomas R. Weiss, MD Radiant Research
San Antonio, TX 78229
110 Concetta Forchetti, MD Radiant Research
Chicago, IL 60610
111 Jack R. Tomlinson, MD Grayline Clinical Drug Trials
Wichita Falls, TX 76309
112 Jimmie Tarro, MD Radiant Research
Portland, OR 97239
113 Fazila Siddiqi, MD Research Across America
Dallas, TX 75234
114 Brian H. Goldman, MD Triangle Medical Research
Raleigh, NC 27609
115 Jay Rubin, MD Renstar Medical Research
Ocala, FL 34471
116 Harvey Schwartz, MD Sunrise Clinical Research
Hollywood, Fl 33021
117 Cynthia Bell, MD Anchor Research Center
Naples, FL 34102Nutrition & Metabolism 2009, 6:31 http://www.nutritionandmetabolism.com/content/6/1/31
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longer period of time than did subjects receiving AC-
1202. Over the course of the study, the AC-1202 group
received a median cumulative dose of 4515 grams over a
period of 90 days (representing 83.9% of the total
intended dose of 5190 grams stipulated by the protocol).
The Placebo group received a median cumulative dose of
4965 grams over a period of 90 days (representing 95. 7%
of intended dose) (Table 4).
Similarly, among both APOE4(-) and APOE4(+) subjects,
mean and median cumulative doses administered in the
Placebo group were greater than the cumulative doses
administered in the AC-1202 group. The cumulative doses
received in APOE4(-) subjects were less than that for
APOE4(+) subjects in the each treatment group. Median
cumulative doses in APOE4(-) subjects was 3780 grams
for AC-1202 subjects and 4950 grams for Placebo sub-
jects. For APOE4(+) subjects, median cumulative dose
was 4740 grams for AC-1202 subjects and 4970 grams in
Placebo subjects (Table 4).
The average number of days on treatment among
APOE4(-) subjects receiving AC-1202 was less than that
observed among the other three cohorts. Median time on
therapy for APOE4(-) subjects receiving AC-1202 was 88
days, whereas the median time on therapy for the other
three cohorts ranged from 90 – 91 days (Table 4).
Outcomes and estimations
ADAS-Cog
Primary outcomes defined by the protocol were change
from Baseline in ADAS-Cog at Day 90 and total CGIC
scores at Day 90. Figure 2A illustrates changes in ADAS-
Cog scores over time in AC-1202 and Placebo ITT groups
relative to Baseline. Change in ADAS-Cog scores were
evaluated at Day 45, Day 90 and Day 104. Since higher
ADAS-Cog scores represent increased impairment, a nega-
tive score in change from Baseline represents an improve-
ment in cognitive performance (note Y axis is reversed in
Figure 2 to illustrate the inverse relationship between
improvement and ADAS-Cog scores). For the ADAS-Cog
in the ITT population, the mean change from Baseline in
subjects administered AC-1202 at Day 90 was -0.31
points, which was not significantly different from Placebo
subjects, who increased 1.23 points (p = 0.077; see Figure
2A, Table 5). On Day 45 the mean change from Baseline
in those administered AC-1202 was -0.177 points, which
was significantly different from Placebo subjects, who
increased 1.73 points (p = 0.024) (Figure 2A, Table 5).
CGIC
For the CGIC, the mean CGIC score in subjects adminis-
tered AC-1202 at Day 90 was 4.21 points, which was not
significantly different from Placebo subjects, whose score
was 4.43 points (p = 0.354; Table 5). The CGIC did not
differ between groups at Day 45.
MMSE
The mean change from Baseline MMSE score in subjects
administered AC-1202 at Day 90 was 0.013 points, which
was not significantly different from Placebo subjects,
whose change was -0.238 points (p = 0.569; Table 5).
Ancillary analyses
Additional analyses as defined by the protocol included:
ability of AC-1202 to induce ketosis, changes in test scores
after the 2 week Washout, and if cognitive scores were
influenced by the presence or absence of an APOE4 allele.
Ketosis
AC-1202 resulted in significantly elevated BHB levels at
all post-dose time points. Screening BHB levels were
within normal ranges and did not differ between groups
(0.11 ± 0.08 mM AC; 0.12 ± 0.11 mM PL, p = 0.590, ± val-
ues indicate SEM). AC-1202 induced a significant eleva-
tion in serum BHB levels on all visit days in which
investigational material was administered (Figure 3). At
Baseline, subjects received 1/2 dose of AC-1202 (10
121 James Goldenberg, MD Visions Clinical Research
Boynton Beach, FL 33437
122 David Steiner, MD Five Towns Neuroscience Institute
Cedarhurst, NY 11516
123 William Petrie, MD Psychiatric Consultants
Nashville, TN 37203
124 Joseph Soufer, MD Phoenix Internal Medicine Associates
Waterbury CT 06708
125 Michael Lesem, MD Claghorn-Lesem Research Clinic
Bellaire, TX 77401
Table 1: Investigators and sites (Continued)Nutrition & Metabolism 2009, 6:31 http://www.nutritionandmetabolism.com/content/6/1/31
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Table 2: Demographic Characteristics
Safety population AC-1202
N = 86
Placebo
N = 66
Age Mean (± SD)
Median
76.9 (± 8.9)
78.0
76.8 (± 7.4)
78.0
Range (52 – 93) (51 – 89)
Height (cms) Mean (± SD) 165.2 (± 11.4) 163.2 (± 16.4)
Median 163.8 164.6
Range (142.2 – 190.1) (114.3 – 185.4)
Weight (kg) Mean (± SD) 69.0 (± 15.15) 70.6 (± 13.7)
Median 69.2 67.8
Range (34.3 – 100.2) (47.6 – 100.2)
Sex n (%) Male 36 (41.7) 31 (47.0)
Female 50 (58.1) 35 (53.0)
Race n (%) Caucasian 78 (90.7) 61 (92.4)
Black 1 (1.2) 0
Hispanic 7 (8.1) 5 (7.6)
Level of Education n (%) Graduate/Professional Training 17 (19.8) 7 (10.6)
Some college 15 (17.4) 17 (25.8)
High School 49 (57.0) 34 (51.5)
Grade School 5 (5.8) 8 (12.1)
AD medications n (%)* Aricept™ 43 (50) 28 (42.4)
Exelon™ 11 (12.8) 11 (16.7)
Namenda™ 32 (37.2) 31 (47)
Reminyl™/Razadyne™ 3 (3.5) 9 (13.6)
Genotyped population AC-1202
N = 67
Placebo
N = 57
APOE Genotype n (%) 3/2 4 (6.0) 2 (3.5)
3/3 25 (37.3) 24 (42.1)
4/2
4/3
3 (4.9)
31 (46.3)
0
21 (36.8)
4/4 4 (6.0) 10 (17.5)
Total E4(+) 38 (56.7) 31 (54.4)
Total E4(-) 29 (43.3) 26 (45.6)
ITT population AC-1202
N = 77
Placebo 
N = 63
Baseline MMSE Mean (± SD) 19.68 (± 4.48) 19.48 (± 4.37)
Median 20.00 20.00
Range (10 – 28) (8 – 29)
95% CI 18.66, 20.69 18.37, 20.58
Baseline ADAS-Cog Mean (± SD) 23.88 (± 9.17) 23.35 (± 8.7)
Median 23.67 23.00
Range (7.00 – 54.33) (11.33 – 62.00)
95% CI 21.80, 25.96 21.16, 25.54
*Some participants were on more than one AD medicationNutrition & Metabolism 2009, 6:31 http://www.nutritionandmetabolism.com/content/6/1/31
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grams) and mean serum BHB increased from 0.09 mM at
pre-dose, to 0.14 mM 2 hours post-dose, which was signif-
icantly different from the Placebo group (p < 0.0001).
Higher post-dose levels of BHB were obtained on Day 45
and Day 90 when subjects were given a full dose (20
grams). Average post-dose BHB values in the AC-1202
group were 0.36 mM on Day 45 and 0.39 mM on Day 90,
both significantly different from Placebo group (p <
0.0001). BHB levels were not different between AC-1202
and Placebo groups at any pre-dose sampling or after the
2 week Washout visit (Figure 3).
Changes after 2 week Washout
On Day 104, after the two week Washout, there was no
significant difference in ADAS-Cog or CGIC in the ITT
population between groups (Figure 2A, Table 5).
Effect of APOE4 status
A previous study had demonstrated that acute administra-
tion of AC-1202 resulted in improvement in ADAS-Cog in
APOE4(-) AD patients [31]. To examine if similar effects
were seen in the present study, the effects of AC-1202
administration on ADAS-Cog, MMSE and CGIC measures
were stratified by APOE4 carriage status. This analysis
examined the 124 subjects who provided written genetic
consent for APOE testing, and used the ITT population
with LOCF.
ADAS-Cog
Among E4(-) patients, those administered AC-1202 per-
formed significantly better on the ADAS-Cog relative to
Placebo at both Day 45 and Day 90. AC-1202 participants
improved -1.72 points over Baseline at Day 45, compared
to a 3.05 point decline in Placebo (p = 0.0005), and
improved -1.75 points over Baseline at Day 90 compared
to a 1.61 point decline in Placebo (p = 0.0148) (Figure 2B,
Table 5). Furthermore, the percentage of E4(-) subjects
experiencing categorical improvements in ADAS-cog
scores were notably higher in the AC-1202 group than in
Placebo. At Day 90, 41.4% (12/29) of E4(-) participants
in the AC-1202 group experienced a -2 point or greater
improvement from Baseline compared to 19% (5/26) in
the Placebo group. In addition, 31% (9/29) experienced a
-4 point or greater improvement compared to 7.7% (2/
26) in the Placebo group, and 13.8% (4/29) experienced
a -10 point or greater improvement compared to 3.8% (1/
26) in the Placebo group. After Washout, among E4(-)
subjects, there was no difference between AC-1202 and
Placebo groups (p = 0.154). Among E4(+) subjects, there
were no significant effects in changes in ADAS-Cog at any
Table 3: Demographic Characteristics by APOE4 status (N)
APOE4(-) APOE4(+) p-value*
Mean Age 76.2 (54) 76.5 (68) 0.796
Mean ADAS-Cog 21.9 (59) 23.4 (69) 0.273
Mean MMSE 20.3 (55) 19.4 (70) 0.239
Sex F 59% (37) F 53% (38)
F = female, M = male M 41% (26) M 47% (34) 0.603
Donepezil N 60% (38) N 47% (34)
Y 40% (25) Y 53% (38) 0.167
Memantine N 70% (44) N 50% (36) 0.023
Y 30% (19) Y 50% (36)
Galantamine N 95% (60) N 92% (66) 0.502
Y 5% (3) Y 8% (6)
Number of AD medications 0 – 30% (19) 0 – 15% (11)
1 – 51% (32) 1 – 44% (32)
2 – 19% (12) 2 – 40% (29) 0.012†
Completed study N 37% (23) N 33% (24) 0.721
Y 63% (40) Y 67% (48)
N = no, Y = yes
*Fisher Exact test
†Contingency analysisNutrition & Metabolism 2009, 6:31 http://www.nutritionandmetabolism.com/content/6/1/31
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time point over the course of the study (Figure 2C,
Table 5).
CGIC
Among E4(-) subjects, those administered AC-1202
showed significantly lower CGIC scores at Day 45 (p =
0.024) compared with Placebo (lower scores indicate
improvement). CGIC scores at Day 90 and Day 104 in the
AC-1202 group were not significantly different from Pla-
cebo (Day 90, p = 0.218; Day 104, p = 0.0877). Among
E4(+) participants, average scores on CGIC were similar to
Placebo at all time points (Table 5).
MMSE
No significant effects were found at any time point regard-
less of genotype (Table 5).
Randomized only subjects
To examine whether the positive results in the ADAS-Cog
test were due to the assignment of new subjects into
groups by the un-blinded monitor (see Methods, Rand-
omization), an analysis was completed on "randomized
only" participants by excluding all subjects intentionally
assigned by the independent, un-blinded monitor.
Among the ITT population, 17 participants were assigned
by the independent monitor; 16 to the AC-1202 and 1 to
Placebo, leaving 61 randomly assigned to AC-1202 and
62 to Placebo. Among the "randomized only" population,
there was no difference in change from Baseline in ADAS-
Cog scores between those administered AC-1202 com-
pared to those administered Placebo on Day 45 (p =
0.0548), Day 90 (p = 0.242), or Day 104 (p = 0.660).
Among E4(-) "randomized only" subjects, those taking
AC-1202 performed significantly better on the ADAS-Cog
relative to Placebo at both Day 45 (4.56 point difference;
p = 0.00123) and at Day 90 (2.68 point difference; p =
0.0457) when compared to Baseline scores (Table 5).
Per protocol subjects
To examine if any bias was present due to the relatively
high dropout rate in the AC-1202 group and the use of
LOCF, an analysis was completed on "per protocol" sub-
jects. Per protocol subjects were defined as subjects who
completed all ADAS-Cog, MMSE and CGIC measures for
Table 4: Total cumulative dosing and treatment duration
Safety population AC-1202
n = 86
Placebo
n = 66
Total Cumulative Dose
Mean dose (grams) ± SD 3555.00 ± 1883.89 4424.55 ± 1326.78
Median 4515 4965
Median percent of intended dose 86.99% 95.66%
(Range) (30, 5460) (150, 5550)
Treatment Duration (days)
N* 82 66
Mean ± SD 71.66 ± 31.08 83.91 ± 18.26
Median 90.0 91.0
(Range) (1, 101) (5, 103)
Genotyped population APOE4(-)
n = 36
APOE4(+)
n = 39
APOE4(-)
n = 27
APOE4(+)
n = 33
Total Cumulative Dose
Mean dose (grams) 3049.17 4015.38 4382.22 4375.45
± SD ± 2076.41 ± 1531.93 1398.93 ± 1386.91
Median 3780 4740 4950 4980
Median percent of intended dose 72.8% 91.3% 95.4% 95.6%
Range (grams) 30 – 5430 30 – 5460 240 – 5490 150 – 5550
Treatment Duration (days)
N* 34 38 27 33
Mean 64.1 77.8 87.1 80.3
± SD ± 36.44 ± 24.3 ± 11.2 +23.3
Median 88.0 90.0 91.0 91.0
Range (days) 3 – 96 1 – 101 56 – 103 5 – 100
*Treatment duration was unknown for 4 AC-1202 subjects for whom last date of study medication was not recordedNutrition & Metabolism 2009, 6:31 http://www.nutritionandmetabolism.com/content/6/1/31
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whom no data were carried forward. All data for per pro-
tocol subjects represent actual scores on that study visit
and no data were imputed.
ADAS-Cog
In the per protocol population (N = 91), there was a sig-
nificant effect between groups in change from Baseline in
ADAS-Cog scores, regardless of genotype, on Day 45 (p =
0.0324) but not at Day 90 (p = 0.192) (Figure 4A, Table
6). As with the ITT population, when this group was strat-
ified by APOE4 status, a significant effect in ADAS-Cog
was observed. Within the per protocol group, E4(-) sub-
jects receiving AC-1202 were significantly different from
Placebo in ADAS-Cog change from Baseline at Day 45
(5.73 point difference, p = 0.0027) and at Day 90 (4.39
point difference, p = 0.0143), but not after Washout (p =
0.321) (Figure 4B, Table 6). There were no significant
effects of AC-1202 in the per protocol E4(+) subjects in
any cognitive outcome measure (Figure 4C, Table 6).
MMSE
In general there were no significant changes in MMSE
scores from Baseline in the per protocol population
between AC-1202 and Placebo groups. Among E4(+) sub-
jects, changes in MMSE score were significantly different
on Day 104. On Day 104, mean change from baseline in
MMSE scores among E4(+) subjects improved one point
in the AC-1202 group, while the Placebo group declined
on average -1.13 points (p = 0.0201).
CGIC
Among E4(-) subjects in the per protocol subgroup, those
administered AC-1202 showed significantly lower CGIC
scores at Day 45 (p = 0.0142) compared with Placebo.
CGIC scores at Day 90 and Day 104 in the AC-1202 group
were not significantly different from Placebo (Day 90, p =
0.1006; Day 104, p = 0.1359). Among E4(+) participants,
average scores on CGIC were similar in both groups at all
time points (Table 6).
Dosage Compliant subjects
To examine the effect of compliance to the dosing sched-
ule on cognitive outcomes, an analysis was completed on
dosage compliant subjects. Dosage compliant subjects
were defined as those that reported consuming a total
cumulative dose of at least 80% of the total intended dose.
Among the 77 AC-1202 subjects, 46 were classified as
compliant and 31 were not. Among the 63 Placebo sub-
jects, 50 were classified as compliant and 13 were not.
Analysis of cognitive outcomes in the compliant popula-
tion was done using the patients scores at each visit, LOCF
was not used in analysis of test scores for compliant sub-
jects. Therefore, this analysis provides insight into changes
in cognitive function among subjects who took the inves-
tigational product and does not use any imputed data.
Mean change in ADAS-Cog scores from Baseline in the ITT  population w/LOCF and stratified by APOE4 carriage status Figure 2
Mean change in ADAS-Cog scores from Baseline in 
the ITT population w/LOCF and stratified by APOE4 
carriage status. Y axis is change from Baseline. X axis is 
time in days. Red circles and lines represent subjects taking 
AC-1202. Blue squares and lines represent subjects taking 
Placebo. Error bars represent standard error of the mean. 
Asterisks (*) indicate a significant (p-value < 0.05) difference 
in mean change from Baseline between AC-1202 and Pla-
cebo. A) Intention to treat subjects (N = 77AC, N = 63PL) 
administered AC-1202 demonstrate a significant difference 
from Placebo at Day 45. B) Genotyped subjects lacking the 
APOE4 allele (APOE4(-)) (N = 29AC, N = 26PL) and admin-
istered AC-1202 demonstrate a significant difference from 
Placebo at Days 45 and 90. C) Genotyped subjects carrying 
the APOE4 allele (APOE4(+)) (N = 38AC, N = 31PL) do not 
differ from Placebo at any time point. For confidence inter-
vals and p-values see Table 5.
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Table 5: Efficacy by visit and genotype in the ITT w/LOCF population*
Group; N AC-1202 Placebo Difference (95% CI) p-value
Day 45 Mean Change From Baseline
ADAS-Cog; ITT w/LOCF
ITT; 77AC, 63PL -0.177 1.730 1.91(0.26, 3.55) 0.0235
APOE4(-); 29AC, 26PL -1.724 3.050 4.77(2.13, 7.41) 0.0005
APOE4(+); 38AC, 31PL 0.904 0.957 0.05(-2.31, 2.42) 0.9644
MMSE; ITT w/LOCF
ITT; 77AC, 63PL 0.013 -0.238 -0.25(-1.12, 0.62) 0.5693
APOE4(-); 29AC, 26PL -0.276 0.038 0.31(-1.05, 1.68) 0.6496
APOE4(+); 38AC, 31PL -0.105 -0.645 -0.54(-1.76, 0.68) 0.3844
CGIC†; ITT w/LOCF
ITT; 61AC, 58PL 4.21 4.43 0.22(-0.25, 0.68) 0.3536
APOE4(-); 23AC, 24PL 4.22 5.04 0.82(0.11, 1.54) 0.0240
APOE4(+); 30AC, 28PL 4.27 3.79 -0.48(-1.12, 0.16) 0.1407
ADAS-Cog; randomized only w/LOCF
ITT; 61AC, 62PL 0.000 1.725 1.73(-0.04, 3.49) 0.0548
APOE4(-); 24AC, 26PL -1.514 3.050 4.56(1.84, 7.29) 0.0012
APOE4(+); 31AC, 30PL 1.054 0.922 0.13(-2.34, 2.60) 0.9161
Day 90 Mean Change From Baseline
ADAS-Cog; ITT w/LOCF
ITT; 77AC, 63PL -0.312 1.227 1.54(-0.17, 3.24) 0.0767
APOE4(-); 29AC, 26PL -1.747 1.614 3.36(0.67, 6.05) 0.0148
APOE4(+); 38AC, 31PL 0.868 0.989 0.12(-2.29, 2.53) 0.9211
MMSE; ITT w/LOCF
ITT; 77AC, 63PL -0.206 -0.299 0.09(-0.81, 0.99) 0.8397
APOE4(-); 29AC, 26PL -0.276 0.385 0.66(-0.80, 2.12) 0.3710
APOE4(+); 38AC, 31PL -0.474 -0.710 -0.24(-1.54, 1.07) 0.7209
CGIC†; ITT w/LOCF
ITT; 64AC, 60PL 4.41 4.62 0.21(-0.29, 0.71) 0.4089
APOE4(-); 23AC, 25PL 4.17 4.68 0.51(-0.30, 1.32) 0.2180
APOE4(+); 33AC, 29PL 4.48 4.38 -0.10(-0.82, 0.61) 0.7698
ADAS-Cog; randomized only w/LOCF
ITT; 61AC, 62PL -0.093 0.908 1.00(-0.68, 2.70) 0.2420
APOE4(-); 24AC, 26PL -1.070 1.614 2.68(0.05, 5.32) 0.0457
APOE4(+); 31AC, 30PL 1.086 0.322 0.76(-1.62, 3.14) 0.5265
Day 104 Mean Change from Baseline
ADAS-Cog; ITT w/LOCF
ITT; 77AC, 63PL -0.113 0.636 0.75(-1.02, 2.52) 0.4046
APOE4(-); 29AC, 26PL -0.736 1.336 2.07(-0.79, 4.93) 0.1540
APOE4(+); 38AC, 31PL 0.544 0.290 -0.25(-2.82, 2.31) 0.8450
MMSE; ITT w/LOCF
ITT; 77AC, 63PL -0.351 -0.619 -0.27(-1.33, 0.79) 0.6177
APOE4(-); 29AC, 26PL -0.586 -0.385 0.20(-1.52, 1.92) 0.8166
APOE4(+); 38AC, 31PL -0.368 -0.968 -0.60(-2.14, 0.94) 0.4421
CGIC†; ITT w/LOCF
ITT; 75AC, 63PL 4.65 4.81 0.16(-0.29, 0.60)) 0.4915
APOE4(-); 28AC, 26PL 4.39 5.00 0.61(-0.09, 1.31) 0.0877
APOE4(+); 37AC, 31PL 4.73 4.48 -0.25(-0.87, 0.31) 0.4369
ADAS-Cog; randomized only w/LOCF
ITT; 61AC, 62PL 0.022 0.431 0.41(-1.43, 2.25) 0.6597
APOE4(-); 24AC, 26PL -0.583 1.336 1.92(-0.99, 4.83) 0.1937
APOE4(+); 31AC, 30PL 0.398 -0.144 0.54(-2.09, 3.17) 0.6838
ITT = Intention-To-Treat; AC = AC-1202; PL = Placebo.
*2 way ANOVA calculated using PROC GLM Type 3 SS. P-values of differences of the type 3 SS LSMEANS.
†CGIC Mean Total scores at Days 45, 90 and 104. Note, some participants did not complete a Day 45 CGIC and no value was carried forward to 
Day 90.Nutrition & Metabolism 2009, 6:31 http://www.nutritionandmetabolism.com/content/6/1/31
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ADAS-Cog
Among the dosage compliant population, there was a sig-
nificant difference in change from Baseline in ADAS-Cog
scores between those administered AC-1202 compared to
those administered Placebo on Day 45 (2.60 point differ-
ence; p = 0.0215), but not on Day 90 (2.26 point differ-
ence; p = 0.064) or Day 104 (1.68 point difference; p =
0.143) (Figure 4A, Table 7). Among E4(-) dosage compli-
ant subjects, there was a significant difference in change
from Baseline in ADAS-Cog scores between those admin-
istered AC-1202 compared to those administered Placebo
on Day 45 (6.26 point difference; p = 0.001) and at Day
90 (5.33 point difference; p = 0.006), but not at Day 104
(3.26 point difference; p = 0.107) (Figure 4B, Table 7).
Among E4(+) compliant subjects, there was no significant
difference in change from Baseline in ADAS-Cog scores
between those administered AC-1202 compared to those
administered Placebo at any time point (Figure 4C,
Table 7).
MMSE
In general there were no significant changes in MMSE
scores from Baseline in the dosage compliant population
between AC-1202 and Placebo groups. Among E4(+) sub-
jects, changes in MMSE score were significantly different
between groups on Day 104. On Day 104, mean change
from baseline in MMSE scores among E4(+) subjects
improved on average 0.524 points in the AC-1202 group,
while the Placebo group declined on average -1.565
points (p = 0.0499) (Table 7).
CGIC
Among E4(-) subjects in the dosage compliant subgroup,
those administered AC-1202 showed significantly lower
CGIC scores at Day 45 (p = 0.05) compared with Placebo.
CGIC scores at Day 90 and Day 104 in the AC-1202 group
were not significantly different from Placebo (Day 90, p =
0.4613; Day 104, p = 0.1547). Among E4(+) participants
in the dosage compliant subgroup, average scores on
CGIC were similar to Placebo at all time points (Table 7).
Total Dose and Change in ADAS-Cog at Day 90
To examine the effect of total dosage on cognitive per-
formance, an analysis was completed correlating the
change from Baseline in ADAS-Cog scores at Day 90 with
total dose reported by each patient. This analysis did not
use LOCF, only actual reported scores were used. Among
subjects of any genotype receiving AC-1202, there was no
significant correlation between total dose and change in
ADAS-Cog at Day 90 (p = 0.2277) (Figure 5A). Among
E4(-) subjects receiving AC-1202, there was a significant
correlation between total dose and change in ADAS-Cog
at Day 90 (p = 0.0493) (Figure 5A). In E4(-) participants,
larger total doses correlated with improved performance
on the ADAS-Cog test (lower scores) (Figure 5A). No sig-
nificant correlations were found in E4(+) subjects receiv-
ing AC-1202 (p = 0.9225), or in any of the groups
receiving Placebo (Figure 5B).
A plot of total dose consumed by each patient in the per
protocol population versus change in ADAS-Cog scores at
Days 45, 90 and 104 is shown in Figure 6. In general, E4(-
) subjects who consumed greater than 4000 grams
showed improvement in ADAS-Cog.
Serum BHB and ADAS-Cog
To examine the effect of elevated BHB on cognitive per-
formance, an analysis was completed on subjects who had
BHB blood draws and ADAS-Cog testing on the same day.
Figure 7 illustrates a correlation between change in ADAS-
Cog scores and serum BHB concentration at Day 90 in the
per protocol population. A significant correlation
between BHB plasma levels and change in ADAS-Cog
scores was observed in the overall population irrespective
of genotype (p = 0.032) (Figure 7A) as well as in E4(-)
subjects (p = 0.008) (Figure 7B). Higher serum BHB con-
centrations correlated with lower ADAS-Cog scores. No
correlation between ADAS-Cog scores and BHB plasma
levels was observed in E4(+) subjects (Figure 7C). An
additional analysis was done removing the non-dosage
Mean pre and post-dose serum BHB levels at each study visit Figure 3
Mean pre and post-dose serum BHB levels at each 
study visit. Post-dose samples were taken 2 hours after 
administration of investigational product. Blue bars represent 
Placebo, red bars represent AC-1202. Error bars represent 
standard error of the mean. Significant increases in BHB lev-
els were found post-dose in AC-1202 subjects compared to 
Placebo subjects. Subjects were given 1/2 dose at Baseline 
(10 grams), full dose on Days 45 and 90 (20 grams), and no 
dose was administered on Day 104. Asterisks (*) represent 
significant differences between AC-1202 and Placebo groups 
(p < 0.0001).
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compliant subjects, yet this did not significantly alter the
outcomes. When non-dosage compliant subjects are
removed from the analyses, a significant correlation was
maintained in both the overall population (p = 0.033)
and among E4(-) participants (p = 0.003) (Figure 7A).
Safety Analyses
Safety assessments were performed for all subjects
enrolled in the study. Gastrointestinal (GI) events were
the most frequently-reported adverse events (AEs) in both
groups. A total of 48.8% of AC-1202 subjects and 27.3%
of Placebo subjects experienced at least one GI AE.
Diarrhea, occurring in 24.4% of AC-1202 and 13.6% of
Placebo subjects, was the most frequently reported AE in
both groups. The proportion of subjects within each
group discontinuing the study for AEs was notably higher
in the AC-1202 group compared with Placebo (23.3% AC;
6.1% PL). After product mixing instructions were
changed, the severity and the number of subjects discon-
tinuing the study for GI AEs notably declined. Prior to the
change in mixing instructions, 3 of 31 (9.7%) AC-1202
subjects experienced severe diarrhea compared with 0 of
27 Placebo subjects. After the mixing instruction change,
the rate of severe diarrhea reported in AC-1202 group
declined to 2 of 64 (3.1%). Likewise, the rate of study dis-
continuations in the AC-1202 group for any type of GI-
related event declined from 7 of 31 (22.6%) before the
change, to 8 of 64 (12.5%) after the change.
In general, no significant differences between groups were
observed for changes in serum chemistry and hematology
values, vital signs, or electrocardiograms. Mean values in
renal function tests increased from screening in the AC-
1202 group, however, the increases did not exceed 2.5 ×
upper limit of normal in any of the subjects and these
changes were not considered clinically significant by the
investigators. Five of seven AC-1202 subjects with notable
elevations in BUN, creatinine, or uric acid levels had
abnormally high values at Screening that were further
increased at Day 104. Among these subjects, three were
noted to have apparent urinary tract infections at study
enrollment, and one had a history of renal failure requir-
ing dialysis prior to enrollment. Furthermore, all of the
subjects with significant renal function test abnormalities
were noted to have BUN/creatinine ratios >15, a likely
indication of dehydration. While the increases in these lab
tests in the AC-1202 group appear to be related to either
pre-existing co-morbidities or to dehydration, a relation
to study investigational product cannot be entirely ruled
out. APOE4 positive and negative subjects receiving AC-
1202 experienced similar rates of adverse events, and nei-
ther the frequency nor the characteristics of these AEs
appeared to be associated with the presence or absence of
the APOE4 allele.
Mean change in ADAS-Cog scores from Baseline in per pro- tocol and dosage compliant populations without LOCF and  stratified by APOE4 carriage status Figure 4
Mean change in ADAS-Cog scores from Baseline in 
per protocol and dosage compliant populations with-
out LOCF and stratified by APOE4 carriage status. Y 
axis is change from Baseline. X axis is time in days. Solid red 
circles and lines represent per protocol subjects taking AC-
1202. Solid blue squares and lines represent per protocol 
subjects taking Placebo. Open red circles and dashed lines 
represent dosage compliant subjects taking AC-1202. Open 
blue squares and dashed lines represent dosage compliant 
subjects taking Placebo. Error bars represent standard error 
of the mean. Asterisks (*) indicate a significant (p-value < 
0.05) difference in mean change from Baseline between AC-
1202 and Placebo. A) Per protocol and dosage compliant 
subjects administered AC-1202 regardless of genotype, both 
cohorts demonstrate a significant difference from Placebo at 
Day 45. B) Per protocol and dosage compliant subjects lack-
ing the APOE4 allele (APOE4(-)) and administered AC-1202 
demonstrate a significant difference from Placebo at both 
Days 45 and 90. C) Per protocol and dosage compliant sub-
jects carrying the APOE4 allele (APOE4(+)) do not differ at 
any time point. For number of subjects, confidence intervals, 
and p-values, see Tables 6 and 7.
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Discussion
Ketogenic diets have been used for over 50 years in a vari-
ety of CNS conditions. For example, in a 3-month rand-
omized controlled trial, a ketogenic diet resulted in an
almost 75% reduction of seizure frequency in childhood
epilepsy [33]. The long-term tolerability and effects of
ketogenic diets have also been previously reported [17]. In
addition, there are preclinical data on the beneficial
effects of intermittent fasting, caloric restriction and
ketogenic diets on brain amyloid deposition and toxicity
(for review see [22]).
Ketogenic diets result in many changes, other than simply
elevating circulating ketone body levels, which may con-
fer neuroprotection. For example, ketogenic diets have
been found to increase levels and activity of uncoupling
Table 6: Efficacy by visit and genotype in the per protocol population*
Group; N AC-1202 Placebo Difference (95% CI) p-value
Day 45 Mean Change From Baseline
ADAS-Cog
PP; 45AC, 46PL -0.600 1.927 2.53(0.22, 4.84) 0.0324
APOE4(-); 18AC, 19PL -2.259 3.472 5.73(2.05, 9.41) 0.0027
APOE4(+); 20AC, 23PL 0.783 0.913 0.13(-3.29, 3.55) 0.9400
MMSE
PP; 45AC, 46PL 0.378 -0.217 0.60(-0.55, 1.74) 0.3060
APOE4(-); 18AC, 19PL 0.000 0.316 0.32(-1.44, 2.07) 0.7207
APOE4(+); 20AC, 23PL 0.350 -0.826 1.18(-0.45, 2.81) 0.1546
CGIC†
PP; 45AC, 46PL 4.00 4.26 0.26(-0.24, 0.76) 0.3040
APOE4(-); 18AC, 19PL 3.94 4.89 0.95(0.20, 1.70) 0.0142
APOE4(+); 20AC, 23PL 4.15 3.61 0.54(-0.16, 1.24) 0.1283
Day 90 Mean Change From Baseline
ADAS-Cog
PP; 45AC, 46PL -0.563 0.956 1.52(-0.78, 3.82) 0.1923
APOE4(-); 18AC, 19PL -2.426 1.963 4.39(0.90, 7.87) 0.0143
APOE4(+); 20AC, 23PL 1.433 0.145 -1.29(-4.53, 1.95) 0.4307
MMSE
PP; 45AC, 46PL -0.261 -0.178 0.08(-1.14, 1.30) 0.8925
APOE4(-); 18AC, 19PL -0.056 0.684 0.74(-1.20, 2.68) 0.4502
APOE4(+); 20AC, 23PL -0.350 -0.913 0.56(-1.24, 2.37) 0.5362
CGIC†
PP; 45AC, 46PL 4.31 4.61 0.29(-0.28, 0.87) 0.3109
APOE4(-); 18AC, 19PL 3.83 4.58 0.75(-0.15, 1.64) 0.1006
APOE4(+); 20AC, 23PL 4.65 4.43 0.22(-0.62, 1.04) 0.6072
Day 104 Mean Change From Baseline
ADAS-Cog
PP; 45AC, 46PL -0.274 0.704 0.98(-1.35, 3.30) 0.4055
APOE4(-); 18AC, 19PL -0.389 1.495 1.88(-1.87, 5.64) 0.3206
APOE4(+); 20AC, 23PL 0.117 0.188 0.07(-3.42, 3.56) 0.9674
MMSE
PP; 45AC, 46PL 0.444 -0.587 1.03(-0.18, 2.24) 0.0941
APOE4(-); 18AC, 19PL -0.111 0.158 0.27(-1.65, 2.19) 0.7813
APOE4(+); 20AC, 23PL 1.000 -1.130 2.13(0.34, 3.92) 0.0201
CGIC†
PP; 45AC, 46PL 4.64 4.78 0.14(-0.44, 0.72) 0.6368
APOE4(-); 18AC, 19PL 4.22 4.89 0.67(-0.22, 1.56) 0.1359
APOE4(+); 20AC, 23PL 4.80 4.52 0.28(-0.55, 1.10) 0.5043
PP = per protocol; AC = AC-1202; PL = Placebo.
*2 way ANOVA calculated using PROC GLM Type 3 SS. P-values of differences of the type 3 SS LSMEANS.
†CGIC Mean Total scores at Days 45, 90 and 104.Nutrition & Metabolism 2009, 6:31 http://www.nutritionandmetabolism.com/content/6/1/31
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proteins [34]. To address whether administration of
ketone bodies alone are neuroprotective, several studies
have examined if infusion of BHB would protect cells
from a variety of cytotoxic agents and conditions. Infusion
of BHB was found to protect rodents from 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) [35], hypoxia
[20,36], traumatic brain injury [37] and glutamate toxicity
[38]. Such studies suggest that ketone bodies alone offer a
possible therapeutic intervention under several condi-
tions (for review see [21]).
In this study, we examined if chronic induction of mild
ketosis would be beneficial to patients with mild to mod-
erate AD. Chronic induction of ketosis in AD patients
Table 7: Efficacy by visit and genotype in the dosage compliant population*
Group; N AC-1202 Placebo Difference (95% CI) p-value
Day 45 Mean Change From Baseline
ADAS-Cog
DC; 46AC, 50PL -0.964 1.639 2.60(0.39, 4.81) 0.0215
APOE4(-); 16AC, 20PL -3.063 3.198 6.26(2.59, 9.94) 0.0011
APOE4(+); 24AC, 24PL 0.361 0.750 0.39(-2.77, 3.55) 0.8073
MMSE
DC; 46AC, 50PL 0.326 -0.220 0.55(-0.57, 1.66) 0.3342
APOE4(-); 16AC, 20PL -0.313 0.350 0.66(-1.12, 2.45) 0.4622
APOE4(+); 24AC, 24PL 0.500 -0.917 1.42(-0.12, 2.95) 0.0701
CGIC†
DC; 44AC, 48PL 4.114 4.313 0.20(-0.32, 0.72) 0.4481
APOE4(-); 16AC, 19PL 4.063 4.895 0.83(0.00, 1.66) 0.0500
APOE4(+); 22AC, 23PL 4.182 3.652 0.53(-0.20, 1.26) 0.1533
Day 90 Mean Change From Baseline
ADAS-Cog
DC; 44AC, 48PL -1.182 1.076 2.26(-0.14, 4.65) 0.0641
APOE4(-); 16AC, 19PL -3.854 1.472 5.33(1.55, 9.11) 0.0063
APOE4(+); 22AC, 24PL 0.909 0.833 0.08(-3.21, 3.36) 0.9635
MMSE
DC; 44AC, 48PL -0.136 -0.271 0.13(-1.1, 1.36) 0.8275
APOE4(-); 16AC, 19PL -0.125 0.789 0.91(-1.09, 2.92) 0.3656
APOE4(+); 22AC, 24PL -0.136 -1.083 0.95(-0.79, 2.69) 0.2820
CGIC†
DC; 43AC, 48PL 4.535 4.521 0.01(-0.56, 0.59) 0.9613
APOE4(-); 16AC, 19PL 4.125 4.474 0.35(-0.59, 1.29) 0.4613
APOE4(+); 21AC, 24PL 4.714 4.375 0.34(-0.49, 1.17) 0.4158
Day 104 Mean Change From Baseline
ADAS-Cog
DC; 43AC, 47PL -0.969 0.682 1.65(-0.75, 4.05) 0.1751
APOE4(-); 16AC, 19PL -1.875 1.389 3.26(-0.72, 7.25) 0.1070
APOE4(+); 21AC, 23PL 0.111 0.449 0.34(-3.21, 3.88) 0.8498
MMSE
DC; 43AC, 47PL 0.186 -0.766 0.95(-0.48, 2.38) 0.1901
APOE4(-); 16AC, 19PL -0.313 0.000 0.31(-2.03, 2.66) 0.7916
APOE4(+); 21AC, 23PL 0.524 -1.565 2.09(0.00, 4.18) 0.0499
CGIC†
DC; 42AC, 46PL 4.667 4.804 0.14(-0.42, 0.70) 0.6248
APOE4(-); 15AC, 19PL 4.267 4.895 0.63(-0.24, 1.50) 0.1547
APOE4(+); 21AC, 22PL 4.857 4.455 0.40(-0.37, 1.17) 0.3002
DC = Dosage Compliant; AC = AC-1202; PL = Placebo.
*2 way ANOVA calculated using PROC GLM Type 3 SS. P-values of differences of the type 3 SS LSMEANS.
†CGIC Mean Total scores at Days 45, 90 and 104.
Note, since this table uses non-imputed data, the number of subjects varies by Visit.Nutrition & Metabolism 2009, 6:31 http://www.nutritionandmetabolism.com/content/6/1/31
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could be achieved by compliance to a ketogenic diet.
However, ketogenic diets require strict adherence to low
carbohydrate intake. Compliance to low carbohydrate
intake may be difficult for Alzheimer's patients due to the
well documented shift in food preference toward sweet,
carbohydrate-rich foods [25,39]. We took advantage of
the unique properties of MCTs to induce ketosis without
the need for dietary change. AC-1202 successfully induced
mild ketosis in AD subjects. Administration of AC-1202 at
10 grams (1/2 recommended amount) at Baseline signifi-
cantly elevated average serum BHB levels by 157%, 2
hours post-dose. Administration of 20 grams of AC-1202
(full recommended amount) significantly elevated aver-
age serum BHB levels by 330% on Day 45 and by 401%
on Day 90. In contrast, in the Placebo group, average
serum BHB levels declined between pre- and post-dose
sampling at each study visit, possibly due to suppression
of endogenous BHB production after eating a carbohy-
drate-rich breakfast. Notably, AC-1202 was able to elevate
serum BHB even when the subjects ate breakfast. These
findings are consistent with the ketogenic properties of
MCTs [30].
AC-1202 is an MCT composed almost entirely of C8:0
fatty acids. It is possible that some beneficial action could
be attributed to the C8 fatty acids rather than ketone bod-
ies. Several reports have implicated MCTs in increasing
fatty acid oxidation with possible roles in weight loss
[40,41]. However, in general, very little C8 reaches the
blood stream after ingestion of an MCT. Medium chain
triglycerides containing C8 fatty acids undergo complete
hydrolysis in the gut lumen. The released C8 are poor sub-
strates for esterification and instead are transported by the
portal vein directly to the liver. Within the liver, C8 fatty
acids undergo obligate oxidation. Thus, very little C8
makes it in to circulation (for overview see [29,30,42]). In
studies in humans dosed with C8 containing MCTs, very
little free C8 is found in aterial blood [43]. While we can-
not entirely rule out the role of C8 fatty acids in mediating
some of the cognitive effects seen in the study, the corre-
lation of cognitive performance with circulating BHB sug-
gests that ketosis plays a prominent role in MCT therapy.
The levels of ketosis obtained with AC-1202 were mild
and similar to those seen in the early phases of very low
carbohydrate diets, and much lower than levels found
during starvation or diabetic ketoacidosis. Very low carbo-
hydrate diets have been examined mainly for weight loss
and management of type II diabetes (for review see [44]).
In studies of low carbohydrate diets, average levels of BHB
after 2 weeks range from 0.4 mM to 0.65 mM, and these
levels frequently decrease over time and may return to
Baseline after 10 to 12 weeks [45-48]. Ketogenic diets dif-
fer from a low carbohydrate diets by imposing stricter lim-
itations on protein intake, and higher, more sustained
Linear fit of change from Baseline at Day 90 in ADAS-Cog  score and log transformed total dosage stratified by APOE4  carriage status Figure 5
Linear fit of change from Baseline at Day 90 in 
ADAS-Cog score and log transformed total dosage 
stratified by APOE4 carriage status. Only reported 
ADAS-Cog scores were used; no data was imputed. Solid cir-
cles represent APOE4(+) subjects, open circles represent 
APOE4(-) subjects. Crosses represent non-dosage compliant 
subjects. Red line indicates linear fit for all genotypes, green 
line for APOE4(-) subjects, and blue line for APOE4(+) sub-
jects. A) Among subjects taking AC-1202, a significant corre-
lation was found in APOE4(-) subjects in change from 
Baseline at Day 90 in ADAS-Cog score and log transformed 
total dosage. B) Among subjects taking Placebo, no signifi-
cant correlations were found in change from Baseline at Day 
90 in ADAS-Cog score and log transformed total dosage.
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Plot of change in ADAS-Cog and total dose administered for each of the per protocol participants Figure 6
Plot of change in ADAS-Cog and total dose administered for each of the per protocol participants. Y axis is 
change in ADAS-Cog score from Baseline. X axis is total dose in grams. Each subject is represented by three symbols. A red x 
represents the change from Baseline score at Day 45. A green square represents the change from Baseline at Day 90. A blue 
diamond represents the change from Baseline at Day 104. APOE4(-) subjects who received more than 4000 grams generally 
improved in ADAS-Cog score.
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levels of BHB (above 1 mM) have been reported [49,50].
As a comparison, much higher levels of serum BHB are
found during 5–6 weeks of starvation (4–8 mM) [51] and
in cases of diabetic ketoacidosis (9–10 mM) [52] (Table
8). AC-1202 induced transient increases of ketosis that
reached average levels of 0.3 to 0.4 mM in the 2 hour post-
dose sample on Days 45 and 90. The positive cognitive
effects noted in E4(-) subjects suggests that higher levels of
ketosis may not be required in AD patients to produce
beneficial outcomes, and that safe, mild elevations in
BHB can be effective.
While the direct effects of ketone bodies on AD metabo-
lism have not been definitively shown, preclinical studies
provide clues as to the possible mechanism of action. The
induction of mild ketosis by AC-1202 in an aged dog
model was found to improve respiration rates in the pari-
etal regions of the brain, by improving mitochondrial
function and reducing mitochondrial oxidative damage
[53]. This is consistent with studies demonstrating
improved mitochondrial function in rat hearts perfused
with BHB [15]. In addition, Kashiwaya et. al. tested the
ability of BHB to protect cultured hippocampal neurons
from the toxic effects of Aβ42. Four millimolar BHB was
found to significantly protect the neurons from Aβ42
[23]. The proposed mechanism of protection was
improved mitochondrial efficiency. In cell culture studies,
incubation with ketone bodies reduced need for glycoly-
sis, increased metabolites in the first third of the TCA
cycle, and increased the redox potential of the NAD/
NADH couple [15]. In addition, exposure to BHB has
been reported to increase autophagy [54] and activate
HIF-1(alpha) [55]. Further experimentation will be
required to understand the precise mechanism whereby
AC-1202 improves cognitive performance in AD patients.
Yet, the rapid response seen in an earlier study [31], sug-
gests that improvement in cellular metabolism plays a
prominent role. For a discussion of the role of ketone bod-
ies in Alzheimer's disease see Henderson [14].
While the cognitive effects were not significant in the over-
all sample, a pre-defined examination of cognitive effects
stratified by genotype yielded significant effects in E4(-)
participants. The ADAS-Cog difference between AC-1202
and Placebo of 4.77 points at Day 45 and 3.36 points at
Day 90 is notable given that many of the subjects in both
groups were already receiving cholinesterase inhibitors
and/or memantine. After the two week Washout (Day
104), there was no difference between groups. E4(+) sub-
jects did not differ between groups at any time point.
Near the end of the study, newly enrolled participants
were intentionally assigned to AC-1202 or Placebo groups
by an independent monitor to balance the number of sub-
jects who completed the study in each group. Since this
Linear fit of change from Baseline at Day 90 in ADAS-Cog  score and log transformed post-dose serum BHB levels in  the per protocol population stratified by APOE4 carriage sta- tus Figure 7
Linear fit of change from Baseline at Day 90 in 
ADAS-Cog score and log transformed post-dose 
serum BHB levels in the per protocol population 
stratified by APOE4 carriage status. Red symbols rep-
resent subjects taking AC-1202. Blue symbols represent sub-
jects taking Placebo. Circles and squares indicate dosage 
compliant subjects, crosses represent non-compliant sub-
jects. The solid lines represent the linear fit in the per proto-
col population. The dashed lines represent the linear fit in 
the dosage compliant sub-population of the per protocol 
population. A) A significant correlation was found in the per 
protocol population between serum BHB levels and change 
in ADAS-Cog on Day 90. B) A significant correlation was 
found in E4(-) per protocol subjects between serum BHB lev-
els and change in ADAS-Cog on Day 90. C) No significant 
correlation was found in E4(+) per protocol subjects 
between serum BHB levels and change in ADAS-Cog on Day 
90. In each case the linear fit of the dosage compliant sub-
group is very similar to the overall per protocol population.
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intentional assignment may have introduced bias into the
study, we conducted an analysis of "randomized only"
subjects. The analysis of the randomized only subjects
mirrors both the ITT w/LOCF population, and the per pro-
tocol population. In each analysis, there is no significant
effect in the primary outcomes. Yet, in each analysis, sig-
nificant effects in change from Baseline in ADAS-Cog
scores compared to Placebo were found in APOE4(-) sub-
jects, at both Day 45 and Day 90. In addition, in each case,
the significant effects on APOE4(-) subjects is lost after the
two week washout (Day 104).
Intention-to-treat w/LOCF analysis is beneficial in that it
captures data from participants who may not have toler-
ated the complete study regimen. Yet, since AD is a pro-
gressive disease, a reliance on the ITT w/LOCF analysis
may have biased the results toward AC-1202, given that
the AC-1202 group experienced a higher dropout rate
compared to the Placebo group. To address this concern,
we conducted an analysis of "per protocol" subjects. Per
protocol subjects were defined as subjects who completed
all study visits and efficacy measures and had no values
carried forward. Despite the relatively small numbers, the
results of the per protocol analyses mirror the ITT w/LOCF
results, with better results seen in the per protocol popu-
lation. Among all per protocol subjects, a 2.53 point dif-
ference between groups in change from Baseline in ADAS-
Cog was found at Day 45 compared to a 1.91 point differ-
ence in the ITT population. As with the ITT w/LOCF anal-
ysis, better efficacy was found in the per protocol E4(-)
sub-population. On Day 45, a 5.73 point difference
between groups in change from Baseline in ADAS-Cog
was found in the E4(-) per protocol population compared
to a 3.05 point difference in the E4(-) ITT population. On
Day 90, a 4.39 point difference between groups in change
from Baseline in ADAS-Cog was found in the E4(-) per
protocol population compared to a 3.36 point difference
in the E4(-) ITT population. The significant differences
found between AC-1202 and Placebo groups in the per
protocol analysis suggest that the positive efficacy results
are not simply due to the use of imputed data. The consist-
ent finding of an effect in E4(-) subjects in the total popu-
lation, per protocol, and randomized only subgroups,
suggests that this result is not due to the introduction of
bias.
If AC-1202 is producing a positive effect in E4(-) subjects,
it is reasonable to hypothesize that such an effect would
be most notable in subjects who complied to the dosing
schedule and actually took a substantial percentage of the
investigational product. This hypothesis is supported by
the analysis of dosage compliant subjects and the correla-
tion between total dosage and improvement in ADAS-Cog
at Day 90. The subjects that demonstrated the most
response to therapy at Day 90 were E4(-) subjects who
were dosage compliant (Figure 8). Among E4(-) subjects,
mean change from Baseline in ADAS-Cog score at Day 90
(independent of Placebo) was -1.7 points in the ITT w/
LOCF population, -2.4 points in the per protocol popula-
tion, and -3.9 points in the dosage compliant population.
Dosage compliant subjects also performed better at Day
45 (-3.1 points) than either the per protocol population (-
2.3 points) or the ITT w/LOCF population (-1.7 points).
In addition, among E4(-) subjects, there was a significant
correlation between total dose administered and change
in ADAS-Cog score from Baseline at Day 90.
The positive effects of AC-1202 in E4(-) subjects is further
supported by analysis of serum BHB levels and cognitive
performance. AC-1202 resulted in significant elevation of
serum BHB relative to Placebo at all study visits when
investigational product was administered. In addition, a
correlation between circulating BHB levels at the two-
hour time point and improvement in ADAS-Cog score
was noted in E4(-) subjects at Day 90. No significant cor-
relation was found in E4(+) participants. Hence, higher
levels of ketosis appear to confer greater benefit in the E4(-
) group.
Table 8: Levels of BHB associated with AC-1202, fasting, and dietary regimens
Intervention Average BHB
levels, mM
Notes Reference
12 hour fast 0.08 – 0.1 Fasting level on typical diet This study, [47,48]
AC-1202 (20 grams) 0.36 2 hour post-dose levels This study
Low carbohydrate diet 0.4 – 0.65 Low carbohydrate diets ranging from 4–10% carbohydrate [45-48]
Ketogenic diet 0.3 – 1.6 Ketogenic diets given to children with refractive epilepsy [49,50]
Starvation 4 – 8 5–6 weeks of complete starvation [51]
Diabetic ketoacidosis 9 – 10 Insulin deficiency and elevated levels of counter-regulatory hormones [52]Nutrition & Metabolism 2009, 6:31 http://www.nutritionandmetabolism.com/content/6/1/31
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A common metric for clinically significant changes in AD
trials is a 4 point change in ADAS-Cog after 6 months.
This is frequently represented as the percent of subjects in
each group who achieved this benchmark [56,57]. In the
present study, participants were only on therapy for 3
months, yet many of the subjects reached this level of
improvement. Among E4(-) subjects receiving AC-1202,
31% (9/29) experienced a -4 point or greater improve-
ment compared to 7.7% (2/26) in the Placebo group at
Day 90. Among E4(-) subjects receiving AC-1202 who
were also dosage compliant, 50% (8/16)) experienced a -
4 point or greater improvement compared to 10% (2/20)
in the Placebo group at Day 90.
We can only speculate on the mechanisms underlying the
genotype-specific effects seen in this study, but there are
reasons to suggest such an effect is not spurious. For exam-
ple, E4(-) AD subjects seem to have greater relative bene-
fits associated with some other therapies, such as infusion
with glucose and insulin [58], nasal insulin, [59] or the
insulin sensitizing agent rosiglitazone [60]. One hypothe-
sis is that there may be lower mitochondrial enzyme func-
tion in E4(+) versus E4(-) as noted in AD brain tissue
samples [61,62]. Reduced mitochondrial function may
inhibit the ability of E4(+) participants to utilize ketone
bodies and this may explain the apparent unresponsive-
ness to AC-1202 reported here.
An alternative explanation may be a differential insulin
sensitivity of AD subjects based on APOE genotype
[10,60,63]. Ketone bodies are transported into the brain
by monocarboxylate transporters [64]. Levels of monocar-
boxylate transporters in the microvasculature are known
to be low in adult mammals, yet elevated in diabetes and
in other conditions where insulin resistance occurs [65].
The milder insulin resistance in E4(-) AD subjects may
allow them to more efficiently import ketone bodies into
the brain and hence respond to AC-1202. Such a model is
consistent with the observation that serum concentrations
of BHB correlated with improvement in cognitive per-
formance in E4(-) subjects, but not in E4(+) subjects.
However, these models remain speculative and further
experimentation will be required to confirm these differ-
ences and underlying mechanisms.
The rapid effects of induced ketosis in an earlier study [31]
and the loss of statistically significant differences in
ADAS-Cog scores after the two week washout, suggests
that AC-1202 may function to improve neuronal or glial
metabolism in the presence of AD pathology, but may not
slow the disease process (at least in a 3 month study).
These results suggest that improvement in cognition may
be feasible by mechanisms that do not address more typ-
ical targets, such as amyloid or tau. Improvement in mito-
chondrial efficiency, or activation of protective pathways,
may provide a viable means to address AD. In support of
this view, in animal models of AD, positive cognitive out-
comes have been reported by interventions that do not
lower amyloid or tau levels. For example, Halagappa et. al.
demonstrated in a triple transgenic mouse model of AD
that an intermittent fasting regime (which may elevate
ketone bodies) produced cognitive benefits without
affecting levels of Aβ or Tau [66].
Limitations
As this is a new area of AD research, our findings must be
interpreted in that context. Participants administered Pla-
cebo demonstrated an unusual degree of worsening in
ADAS-Cog scores at Day 45. The magnitude of this change
is somewhat unexpected, although other studies have
reported similar rates of decline [67,68]. The lack of
strong efficacy in MMSE and CGIC may be due to relative
insensitivity of these tests, the small number of subjects,
and/or the short duration of the trial. In addition, the
reported deviations in the CGIC assessment scales cau-
tions against over-interpretation of these results. The rela-
tively high drop outs due to GI effects with our initial
dosing regimen led to an intentional assignment by an
independent monitor of a small number of subjects to the
Placebo and AC-1202 groups, yet this did not appear to
influence the overall outcome. It is possible that GI side
effects might have biased outcomes in some subtle man-
ner, although it must be noted that high rates of GI side
effects are also noted in cholinesterase inhibitor trials.
Group randomization was not stratified by APOE geno-
type, yet distribution of APOE4 alleles was similar
between groups. Lastly, since this was a 3-month trial, this
study cannot address the safety and efficacy of longer peri-
ods of administration.
Conclusion
Due to the unique mechanism of action of AC-1202, par-
ticipants were allowed to continue on stable concomitant
AD treatments. Approximately 80% of the subjects in
both groups were on one form of AD therapy. Despite
being tested in a non-naïve population, AC-1202 resulted
in significant improvement in the ADAS-Cog test in E4(-)
AD patients relative to Placebo. The GI side effects were
predictable, and data from this trial will allow further
optimization of the administration of AC-1202 to mini-
mize such events. Therefore, chronic induction of ketosis
may offer a novel strategy for AD that can be used with
current therapies.
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Summary graph of mean change from Baseline at Day 90 for ITT w/LOCF, per protocol and dosage compliant groups stratified  by APOE4 carriage status Figure 8
Summary graph of mean change from Baseline at Day 90 for ITT w/LOCF, per protocol and dosage compliant 
groups stratified by APOE4 carriage status. Red columns represent subjects receiving AC-1202. Blue columns represent 
subjects receiving Placebo. Error bars represent standard error of the mean. Table displays mean change from Baseline for 
each group. Mean changes from Baseline was largest in APOE4(-) subjects who were dosage compliant.
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